Search Results - "STAIN, A."

Haemophilia in the first years of life by LJUNG, R., CHAMBOST, H., STAIN, A.-M., DIMICHELE, D.

“…Surgery in infants and young children with haemophilia, when preceded by accurate diagnosis and accompanied by safe and effective factor prophylaxis, is not…”
Get full text

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010 by Vézina, C., Carcao, M., Infante-Rivard, C., Lillicrap, D., Stain, A. M., Paradis, E., Teitel, J., Rivard, G. E.

“…Summary The objective of this study was to evaluate the inhibitor development (ID) in previously untreated patients (PUPs) with severe haemophilia A…”
Get full text

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A by Sharathkumar, A., Lillicrap, D., Blanchette, V. S., Kern, M., Leggo, J., Stain, A. M., Brooker, L., Carcao, M. D.

“…Background: Inhibitors are rare in boys with mild hemophilia A (MHA; factor (F)VIII:C > 5%) but may arise following intense FVIII exposure, e.g. continuous…”
Get full text

Consequences of delayed therapy for sports-related bleeds in patients with mild-to-moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis by Kumar, R., Stain, A. M., Hilliard, P., Carcao, M.

Get full text

Intracranial haemorrhage in von Willebrand disease: a report on six cases by Labarque, V., Stain, A. M., Blanchette, V., Kahr, W. H. A., Carcao, M. D.

“…Summary The incidence of intracranial haemorrhage (ICH) in von Willebrand disease (VWD) is not well documented. We describe our single centre experience…”
Get full text

Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS) by Langley, A. R., Stain, A. M., Chan, A., McLimont, M., Chait, S., Wu, J., Poon, M.-C., Card, R., Israels, S. J., Laferriere, N., Klaassen, R. J., Rivard, G. E., Cloutier, S., Hawes, S., Feldman, B., Blanchette, V.

“…Introduction Haemophilia A treatment with factor VIII concentrates requires frequent venipunctures; a central venous access device (CVAD) may be required to…”
Get full text

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience by CARCAO, M., ST LOUIS, J., POON, M-C., GRUNEBAUM, E., LACROIX, S., STAIN, A. M., BLANCHETTE, V. S., RIVARD, G. E.

“…When a high titre inhibitor develops in a patient with haemophilia, attempts are made to eradicate it through immune tolerance induction therapy (ITI)…”
Get full text

von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay by Dean, J A, Blanchette, V S, Carcao, M D, Stain, A M, Sparling, C R, Siekmann, J, Turecek, P L, Lillicrap, D, Rand, M L

“…Definitive diagnosis of type 1 von Willebrand Disease (VWD) remains a problem. Provisional consensus guidelines for the diagnosis of definite and possible type…”
Get more information

Sonography for assessment of haemophilic arthropathy in children: a systematic protocol by ZUKOTYNSKI, K., JARRIN, J., BABYN, P. S., CARCAO, M., PAZMINO-CANIZARES, J., STAIN, A. M., DORIA, A. S.

“…Radiological imaging of joints in children with haemophilia is important to detect abnormalities, grade their severity and monitor the effects of treatment…”
Get full text

Hepatitis A and B immunization for individuals with inherited bleeding disorders by STEELE, M., COCHRANE, A., WAKEFIELD, C., STAIN, A-M., LING, S., BLANCHETTE, V., GOLD, R., FORD-JONES, L.

“…Hepatitis A and B vaccines are highly effective tools that can greatly reduce infection risk in the bleeding disorder population. Although hepatitis A and B…”
Get full text

Preference-Based Measurement of Health-Related Quality of Life (HRQL) in Children with Chronic Musculoskeletal Disorders (MSKDs) by Brunner, H. I., Maker, D., Grundland, B., Young, N. L., Blanchette, V., Stain, A-M., Feldman, B. M.

“…Background. Health-related quality of life can be measured by patients' health preferences (utilities or values). No method for measuring health state…”
Get full text

Effect of intracranial bleeds on the neurocognitive, academic, behavioural and adaptive functioning of boys with haemophilia by MILES, B. S., ANDERSON, P., AGOSTINO, A., GOLOMB, M. R., ACHONU, C., BLANCHETTE, V., FELDMAN, B. M., McLIMONT, M., REVEL-VILK, S., STAIN, A., BARNES, M. A.

“…Brain insults are a risk factor for neuropsychological and academic deficits across several paediatric conditions. However, little is known about the specific…”
Get full text

A prospective, longitudinal study of central venous catheter‐related deep venous thrombosis in boys with hemophilia by Price, V. E., Carcao, M., Connolly, B., Chait, P., Daneman, A., Temple, M., Stain, A. M., Sung, L., Al‐Tralbosi, H., Blanchette, V. S.

“…Background: Central venous catheters (CVCs) are often inserted into boys with hemophilia to secure venous access for factor prophylaxis and immune tolerance…”
Get full text

The Platelet Function Analyzer (PFA‐100®): a novel in‐vitro system for evaluation of primary haemostasis in children by CARCAO, M. D, BLANCHETTE, V. S, RAND, M. L, DEAN, J. A, HE, L, KERN, M. A, STAIN, A. M, SPARLING, C. R, STEPHENS, D, RYAN, G, FREEDMAN, J

“…The PFA‐100® system provides an in‐vitro method of assessing primary platelet‐related haemostasis by measuring the time (the closure time, or CT) taken for a…”
Get full text

Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding by TRAIVAREE, C., BLANCHETTE, V., ARMSTRONG, D., FLOROS, G., STAIN, A. M., CARCAO, M. D.

“…We conducted a review of a single institutional experience of patients with haemophilia presenting with suspected intracranial haemorrhage (ICH) who underwent…”
Get full text

The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity by REVEL-VILK, S., KOMVILAISAK, P., BLANCHETTE, V., STAIN, A. M., FLOROS, G., COCHRANE, A., BLANCHETTE, C., HANG, M., ROBERTS, E. A., LING, S. C.

“…Hepatitis in children with haemophilia was historically most often associated with transfusion‐transmitted infections. However, with the use of recombinant…”
Get full text

Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique by NARAINE, V. S., RISEBROUGH, N. A., OH, P., BLANCHETTE, V. S., LEE, S., STAIN, A-M., HEDDEN, D., TEITEL, J. M., FELDMAN, B. M.

“…Prophylaxis for haemophilia improves outcomes, but at a substantial cost. Cost–utility analysis balances improvements seen in health‐related quality of life…”
Get full text

Dental disease in type 3 Von Willebrand disease: a neglected problem by CARCAO, M. D., SEARY, M. E., CASAS, M., WINTER, L., STAIN, A. M., JUDD, P.

“…Type 3 Von Willebrand disease (VWD) is a rare, severe, autosomal recessive bleeding disorder. In our institution, we follow 17 children with type 3 VWD. We…”
Get full text

Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors by Carcao, M. D., Connolly, B. L., Chait, P., Stain, A. M., Acebes, M., Massicotte, P., Blanchette, V. S.

“…We report the case of a 10.5‐year‐old boy with severe haemophilia A (SHA) and inhibitors who presented with superior vena cava (SVC) obstruction while on…”
Get full text

A survey of factor prophylaxis in the Canadian haemophilia A population by Blanchette, P., Rivard, G., Israels, S., Robinson, S., Ali, K., Walker, I., Stain, A. M., Blanchette, V.

“…High‐dose factor prophylaxis, defined as the infusion of 25–40 factor (F) VIII International Units (IU) kg bodyweight (bw)−1≥ × 3 per week, started at age 1–2…”
Get full text